stoxline Quote Chart Rank Option Currency Glossary
  
Supernus Pharmaceuticals, Inc. (SUPN)
30.24  -1.76 (-5.5%)    04-12 16:00
Open: 31.98
High: 31.98
Volume: 358,750
  
Pre. Close: 32
Low: 30.08
Market Cap: 1,655(M)
Technical analysis
2024-04-12 4:52:27 PM
Short term     
Mid term     
Targets 6-month :  39 1-year :  41.39
Resists First :  33.39 Second :  35.43
Pivot price 32.81
Supports First :  30.07 Second :  25.02
MAs MA(5) :  31.44 MA(20) :  33.22
MA(100) :  29.44 MA(250) :  30.27
MACD MACD :  -0.1 Signal :  0.4
%K %D K(14,3) :  19.4 D(3) :  22.6
RSI RSI(14): 39.4
52-week High :  39.09 Low :  21.98
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ SUPN ] has closed below the lower bollinger band by 6.7%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 28.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 32 - 32.16 32.16 - 32.29
Low: 29.71 - 29.88 29.88 - 30.01
Close: 29.98 - 30.26 30.26 - 30.47
Company Description

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.

Headline News

Wed, 10 Apr 2024
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by State of Alaska Department of Revenue - Defense World

Mon, 08 Apr 2024
Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease - Yahoo Finance

Mon, 08 Apr 2024
Supernus stock slides as FDA rejects Parkinson's disease infusion device (NASDAQ:SUPN) - Seeking Alpha

Mon, 08 Apr 2024
Supernus Provides Regulatory Update for SPN-830 - GlobeNewswire

Sun, 07 Apr 2024
Trust Point Inc. Invests $325000 in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World

Mon, 01 Apr 2024
Vanguard Group Inc. Acquires 28711 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 55 (M)
Shares Float 48 (M)
Held by Insiders 5.1 (%)
Held by Institutions 107.8 (%)
Shares Short 4,920 (K)
Shares Short P.Month 4,030 (K)
Stock Financials
EPS 0.01
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 16.84
Profit Margin 0.2 %
Operating Margin 11.5 %
Return on Assets (ttm) 0.5 %
Return on Equity (ttm) 0.1 %
Qtrly Rev. Growth -1.8 %
Gross Profit (p.s.) 0
Sales Per Share 11.1
EBITDA (p.s.) 1.79
Qtrly Earnings Growth -96 %
Operating Cash Flow 111 (M)
Levered Free Cash Flow 162 (M)
Stock Valuations
PE Ratio 1512
PEG Ratio 11.9
Price to Book value 1.79
Price to Sales 2.72
Price to Cash Flow 14.89
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android